Batu Biologics CEO Selected for Lyfebulb Oncology Award

Batu Biologics CEO Selected as Finalist for Lyfebulb-Helsinn Innovation Summit and Award For Oncology

Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology

Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, today announced the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology.

Read the full article at globalnewswire.com